Biomarker-informed care for patients with renal cell carcinoma
- PMID: 40240621
- DOI: 10.1038/s43018-025-00942-1
Biomarker-informed care for patients with renal cell carcinoma
Abstract
Kidney cancer is a commonly diagnosed cancer in adults, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Immune checkpoint inhibitors have revolutionized care for patients with ccRCC, either as adjuvant therapy or combined with other agents in advanced disease. However, biomarkers to predict therapeutic benefits are lacking. Here, we explore biomarkers that predict therapeutic response in other tumor types and discuss the reasons for their ineffectiveness in ccRCC. We also review emerging predictive and prognostic biomarkers to prioritize in ccRCC, including gene expression signatures.
© 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
Competing interests: M.B.M. has nothing to disclose. B.I.R. is a consultant for and receives research funding from Merck, Eisai, Genentech, BMS and Pfizer. S.M.H. is a consultant for Exelixis and Tempus.
Similar articles
-
DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.Int J Biol Sci. 2021 Jul 25;17(12):3158-3172. doi: 10.7150/ijbs.62553. eCollection 2021. Int J Biol Sci. 2021. PMID: 34421357 Free PMC article.
-
Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinoma.Eur J Med Res. 2024 Jul 20;29(1):378. doi: 10.1186/s40001-024-01939-9. Eur J Med Res. 2024. PMID: 39033192 Free PMC article.
-
TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma.Front Immunol. 2024 Sep 5;15:1457691. doi: 10.3389/fimmu.2024.1457691. eCollection 2024. Front Immunol. 2024. PMID: 39301023 Free PMC article.
-
Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.Front Immunol. 2021 Mar 4;12:653358. doi: 10.3389/fimmu.2021.653358. eCollection 2021. Front Immunol. 2021. PMID: 33746989 Free PMC article. Review.
-
The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma.J Cell Physiol. 2018 Jun;233(6):4458-4465. doi: 10.1002/jcp.26347. Epub 2017 Dec 26. J Cell Physiol. 2018. PMID: 29215721 Review.
Cited by
-
Biomarkers for renal cell carcinoma - a pragmatic approach.Nat Rev Urol. 2025 Jul 30. doi: 10.1038/s41585-025-01073-z. Online ahead of print. Nat Rev Urol. 2025. PMID: 40739448 No abstract available.
-
Regulatory T cells and matrix-producing cancer associated fibroblasts contribute on the immune resistance and progression of prognosis related tumor subtypes in ccRCC.Sci Rep. 2025 Jul 1;15(1):20533. doi: 10.1038/s41598-025-06051-4. Sci Rep. 2025. PMID: 40596367 Free PMC article.
References
-
- Atkins, M. B. Clinical presentation, diagnosis, and staging of renal cell carcinoma. In UpToDate (ed. Richie, J. P.) (Wolters Kluwer, 2023).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical